Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
91,71 CHF | +1,14% |
|
+3,18% | +3,22% |
Beschrijving van de bedrijfsactiviteiten: Novartis AG
- oncologie (29,3%)
- immunologie (18,5%)
- cardiovasculaire, renale en metabolische ziekten (17%);
- neurowetenschap (9,4%).
De resterende netto-omzet (25,8%) is afkomstig van contractproductie van farmaceutische producten.
Eind 2024 had Novartis AG wereldwijd meer dan 30 productielocaties.
De netto-omzet is geografisch als volgt verdeeld: Europa (30,9%), de Verenigde Staten (42%), Azië/Afrika/Australië (20%), Canada en Latijns-Amerika (7,1%).
Aantal werknemers: 75.883
Verdeling van verkoop per activiteit: Novartis AG
Start boekjaar: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Innovative Medicines | 40,82 mld. | 43,97 mld. | 43,37 mld. | 46,66 mld. | 51,72 mld. |
Sandoz | 9,89 mld. | 9,87 mld. | 9,48 mld. | - | - |
Corporate (Including Eliminations) | -813 mln. | -964 mln. | -1,02 mld. | - | - |
Geografische uitsplitsing van de verkoop: Novartis AG
Start boekjaar: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States | 16,48 mld. | 16,82 mld. | 17,65 mld. | 17,96 mld. | 21,15 mld. |
Other | 19,04 mld. | 20,81 mld. | 20,05 mld. | 15,87 mld. | 18,51 mld. |
China | 2,57 mld. | 3,05 mld. | 3,13 mld. | 3,27 mld. | 3,89 mld. |
Germany | 4,52 mld. | 4,87 mld. | 4,28 mld. | 3,37 mld. | 3,66 mld. |
France | 2,44 mld. | 2,52 mld. | 2,26 mld. | 1,75 mld. | 1,79 mld. |
Switzerland | 800 mln. | 873 mln. | 970 mln. | 1,31 mld. | 1,32 mld. |
Japan | 2,8 mld. | 2,68 mld. | 2,2 mld. | 1,92 mld. | - |
Uitvoerend comité: Novartis AG
Bedrijfsleider | Titel | Leeftijd | Van |
---|---|---|---|
Algemeen Directeur | 49 | 01-02-2018 | |
Financieel Directeur/CFO | 60 | 24-04-2013 | |
Shreeram Aradhye
CTO | Hoofd Techniek/Wetenschap/O&O | 63 | 16-05-2022 |
Karen Hale
CMP | Compliance Officer | 57 | 14-04-2025 |
Steffen Lang
COO | Operationeel Directeur | 58 | 04-04-2022 |
Samenstelling van de raad van bestuur: Novartis AG
Directeur | Titel | Leeftijd | Van |
---|---|---|---|
Nancy Andrews
BRD | Directeur/Bestuurslid | 66 | 01-01-2015 |
Liz Doherty
BRD | Directeur/Bestuurslid | 68 | 01-01-2016 |
Ton Büchner
BRD | Directeur/Bestuurslid | 60 | 01-01-2016 |
Frans van Houten
BRD | Directeur/Bestuurslid | 65 | 28-02-2017 |
Patrice Bula
BRD | Directeur/Bestuurslid | 69 | 28-02-2019 |
Bridgette Heller
BRD | Directeur/Bestuurslid | 63 | 28-02-2020 |
Simon Moroney
BRD | Directeur/Bestuurslid | 66 | 28-02-2020 |
Directeur/Bestuurslid | 58 | 04-03-2022 | |
Directeur/Bestuurslid | 65 | 04-03-2022 | |
John Young
BRD | Directeur/Bestuurslid | 61 | 07-03-2023 |
Participaties: Novartis AG
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
NOVARTIS AG 6,79% | 148.621.654 | 6,79% | 16.435.312.232 $ |
NOVARTIS INDIA LIMITED 70,68% | 17.450.680 | 70,68% | 160.281.529 $ |
OCULIS HOLDING AG 3,57% | 1.713.521 | 3,57% | 32.608.305 $ |
ERASCA, INC. 4,35% | 12.307.692 | 4,35% | 16.861.538 $ |
THIRD HARMONIC BIO, INC. 5,87% | 2.642.762 | 5,87% | 9.170.384 $ |
MOLECULAR PARTNERS AG 4,31% | 1.739.130 | 4,31% | 6.997.807 $ |
413.581 | 5,24% | 1.972.781 $ |
Bedrijfsgegevens: Novartis AG

Bedrijven van de groep: Novartis AG
Naam | Categorie en sector |
---|---|
Novartis Healthcare Pvt Ltd.
![]() Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Investment Ltd. | |
Novartis Holding AG
![]() Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. |
Financial Conglomerates
|
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
![]() Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Services, Inc. is a pharmaceutical company. The company is based in Cambridge, MA. |
Pharmaceuticals: Major
|
Farmaceutische producten - Andere
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Varia. 1j. | Varia. 3j. | Kapi.($) | |
---|---|---|---|---|---|---|
+1,14% | +3,18% | +4,81% | +6,17% | 212 mld. | ||
+1,16% | +9,70% | +13,16% | +185,74% | 743 mld. | ||
+0,53% | +2,20% | +5,79% | -13,97% | 380 mld. | ||
+2,13% | -2,97% | +3,51% | +9,63% | 307 mld. | ||
+3,37% | -7,70% | -54,04% | +4,37% | 266 mld. | ||
+1,65% | +2,62% | +14,39% | -29,48% | 251 mld. | ||
+2,05% | +0,14% | -8,14% | -1,62% | 210 mld. | ||
+1,44% | -0,25% | -37,79% | -8,42% | 199 mld. | ||
+1,72% | -5,28% | +2,39% | +8,98% | 150 mld. | ||
+1,13% | -0,93% | +57,60% | +65,51% | 132 mld. | ||
Gemiddelde | +1,14% | -0,43% | +0,17% | +22,69% | 285,02 mld. | |
Gewogen gemiddelde per kap. | +1,15% | +1,48% | +0,71% | +48,66% |
Sector

Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers NOVN
- Onderneming Novartis AG